{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Musisi E"],"funding":["Bundesministerium für Bildung und Forschung","European & Developing Countries Clinical Trials Partnership (EDCTP)","Medical Research Council"],"pagination":["e913-e922"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7617392"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(11)"],"pubmed_abstract":["<h4>Background</h4>Respiratory tract microbiota has been described as the gatekeeper for respiratory health. We aimed to assess the impact of standard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes.<h4>Methods</h4>In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regimens versus standard-of-care who were part of the HIGHRIF study 2 (NCT00760149) and PanACEA MAMS-TB (NCT01785186) clinical trials across a 3-month treatment follow-up period. Samples were from participants in Mbeya, Kilimanjaro, Bagamoyo, and Dar es Salaam, Tanzania. Experimental regimens were composed of different combinations of rifampicin (R), isoniazid (H), pyrazi"],"journal":["The Lancet. Microbe"],"pubmed_title":["Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials."],"pmcid":["PMC7617392"],"funding_grant_id":["IP.2007·32011·013","MC_UU_00004/04","MC_UU_12023/27","IP.2007·32011·011","01KA0901"],"pubmed_authors":["Kibiki GS","Adegbite BR","Reither K","Hoelscher M","Sanne I","Sabiiti W","Nunn AJ","Adegnika AA","Massango I","Brake LT","Sam N","Boeree M","Grobusch MP","Twabi HH","Sloan D","Rassool M","Manyama C","Hunt R","PanACEA consortium","Jani I","Diacon A","Dawson R","Nliwasa M","Hoffmann L","Musisi E","de Jager V","Mbeya B","Lutchmun W","Sabi I","Liyoyo A","Narunsky K","Mpagama S","Khosa C","Mtafya B","Demel PG","Semvua H","Mhimbira F","Honeyborne I","Norena I","Eldirdiri S","Gong X","Ssengooba W","Mangu C","Jugheli L","Mmbaga BT","Kelly A","Dreisbach J","Ntinginya NE","Joloba M","Gillespie S","Gillespie SH","Kirenga B","McHugh TD","Heinrich N","Aarnoutse R","Wyness A","Msefula CL","Dombay E","Sasamalo M","Svensson E","Mukoka M","Friedrich S","Wildner LM","Phillips PPJ","Minja LT","Azam K"],"additional_accession":[]},"is_claimable":false,"name":"Effect of seven anti-tuberculosis treatment regimens on sputum microbiome: a retrospective analysis of the HIGHRIF study 2 and PanACEA MAMS-TB clinical trials.","description":"<h4>Background</h4>Respiratory tract microbiota has been described as the gatekeeper for respiratory health. We aimed to assess the impact of standard-of-care and experimental anti-tuberculosis treatment regimens on the respiratory microbiome and implications for treatment outcomes.<h4>Methods</h4>In this retrospective study, we analysed the sputum microbiome of participants with tuberculosis treated with six experimental regimens versus standard-of-care who were part of the HIGHRIF study 2 (NCT00760149) and PanACEA MAMS-TB (NCT01785186) clinical trials across a 3-month treatment follow-up period. Samples were from participants in Mbeya, Kilimanjaro, Bagamoyo, and Dar es Salaam, Tanzania. Experimental regimens were composed of different combinations of rifampicin (R), isoniazid (H), pyrazi","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2026-06-01T19:21:39.963Z","creation":"2025-04-06T22:25:40.71Z"},"accession":"S-EPMC7617392","cross_references":{"pubmed":["37832571"],"doi":["10.1016/S2666-5247(23)00191-X"]}}